Title :

Therapeutic management in ambulatory elderly patients with atrial fibrillation: the s. Ages cohort

Author(s) :

Hanon, Olivier [Auteur]
Vidal, Jean-Sébastien [Auteur]
Pisica-Donose, G. [Auteur]
Benattar-Zibi, Linda [Auteur]
Bertin, Philippe [Auteur]
Berrut, Gilles [Auteur]
Corruble, Emmanuelle [Auteur]
Derumeaux, Genevieve [Auteur]
Falissard, Bruno [Auteur]
Forette, Françoise [Auteur]
Pasquier, Florence [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Pinget, Michel [Auteur]
Ourabah, Rissane [Auteur]
Becquemont, Laurent [Auteur]
Danchin, Nicolas [Auteur]

Journal title :

The journal of nutrition, health & aging

Abbreviated title :

J. Nutr. Health Aging

Volume number :

19

Pages :

219-227

Publication date :

2015-02-01

ISSN :

1279-7707

English keyword(s) :

elderly
Atrial fibrillation
anticoagulation
vitamin K antagonists

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Few epidemiologic studies have specifically focused on very old community dwelling population with atrial fibrillation (AF). The objectives of the AF-S.AGES cohort were to describe real-life therapeutic management of ...
Show more >Few epidemiologic studies have specifically focused on very old community dwelling population with atrial fibrillation (AF). The objectives of the AF-S.AGES cohort were to describe real-life therapeutic management of non-institutionalized elderly patients with AF according to age groups, i.e., 65-79 and ≥ 80 and to determine the main factors associated with anticoagulant treatment in both groups. METHODS: Observational study (N=1072) aged ≥ 65 years old, recruited by general practitioners. Characteristics of the sample were first evaluated in the overall sample and according to age (< 80 or ≥ 80 years) and to use of anticoagulant treatment at inclusion. Logistic models were used to analyze the determinants of anticoagulant prescription among age groups. RESULTS: Mean age was 78.0 (SD=6.5) years and 42% were ≥ 80 years. Nineteen percent had paroxysmal AF, 15% persistent, 56% permanent and 10% unknown type, 77% were treated with vitamin K antagonists (VKA), 17% with antiplatelet therapy with no differences between age groups. Rate-control drugs were more frequently used than rhythm-control drugs (55% vs. 37%, p < 0.001). VKA use was associated with permanent AF, younger age and cancer in patients ≥ 80 years old and with permanent AF and preserved functional autonomy in patients < 80 years old. Hemorrhagic scores were independently associated with non-use of VKA whereas thromboembolic scores were not associated with VKA use. CONCLUSIONS: In this elderly AF outpatient population, use of anticoagulant therapy was higher even after 80 years than in previous studies suggesting that recent international guidelines are better implemented in the elderly population.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
CNRS
Inserm
Université de Lille

Collections :

• Lille Neurosciences & Cognition (LilNCog) - U 1172

Research team(s) :

Troubles cognitifs dégénératifs et vasculaires

Submission date :

2019-11-27T14:28:32Z